Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.
Kwon, Janice S; McTaggart-Cowan, Helen; Ferguson, Sarah Eet al.
2024 • In Journal of Gynecologic Oncology, 35 (6), p. 117
Cost-Effectiveness; Early Stage Cervical Cancer; Health Utility; Low Risk; Quality-Adjusted Life Expectancy; Radical Hysterectomy; Simple Hysterectomy; Humans; Female; Middle Aged; Quality of Life; Adult; Neoplasm Recurrence, Local; Neoplasm Staging; Cost-Effectiveness Analysis; Uterine Cervical Neoplasms/surgery; Uterine Cervical Neoplasms/economics; Uterine Cervical Neoplasms/pathology; Hysterectomy/methods; Hysterectomy/economics; Cost-Benefit Analysis; Quality-Adjusted Life Years; Markov Chains; Hysterectomy; Uterine Cervical Neoplasms; Oncology; Obstetrics and Gynecology
Abstract :
[en] [en] OBJECTIVE: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health. The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
METHODS: Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
RESULTS: Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs. radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
CONCLUSION: Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01658930.
Disciplines :
Oncology Reproductive medicine (gynecology, andrology, obstetrics) Human health sciences: Multidisciplinary, general & others
Author, co-author :
Kwon, Janice S ; University of British Columbia, Vancouver, Canada. Janice.Kwon@vch.ca
McTaggart-Cowan, Helen ; BC Cancer, Vancouver, Canada
Ferguson, Sarah E ; Princess Margaret Cancer Centre, Toronto, Canada
Samouëlian, Vanessa ; Centre Hospitalier de l'Université de Montréal, Montréal, Canada
Lambaudie, Eric ; Institut Paoli-Calmettes, Marseille, France
Guyon, Frédéric ; Institut Bergonie, Bordeaux, France
Tidy, John ; Royal Hallamshire Hospital, Sheffield, United Kingdom
Williamson, Karin ; Nottingham University Hospitals, Nottingham, United Kingdom
Gleeson, Noreen ; St James' Hospital, Dublin, Ireland
de Kroon, Cor ; Leiden University Medical Center, Leiden, Netherlands
van Driel, Willemien ; Netherlands Cancer Institute, Amsterdam, Netherlands
Mahner, Sven ; LMU University Hospital, Munich, Germany
Hanker, Lars ; University Hospital Schleswig-Holstein, Lubeck, Germany
Goffin, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques
Berger, Regina ; Medical University Innsbruck, Innsbruck, Austria
Eyjólfsdóttir, Brynhildur ; The Norwegian Radium Hospital, Oslo, Norway
Kim, Jae-Weon ; Seoul National University College of Medicine, Seoul, Korea
Brotto, Lori A ; University of British Columbia, Vancouver, Canada
Pataky, Reka ; BC Cancer, Vancouver, Canada
Yeung, Shirley S T ; BC Cancer, Vancouver, Canada
Chan, Kelvin K W ; Sunnybrook Health Sciences Centre and Odette Cancer Centre, University of Toronto, Canada
Cheung, Matthew C ; Sunnybrook Health Sciences Centre and Odette Cancer Centre, University of Toronto, Canada
Ubi, Juliana; Canadian Cancer Trials Group, Queen's University, Kingston, Canada
Tu, Dongsheng ; Canadian Cancer Trials Group, Queen's University, Kingston, Canada
Shepherd, Lois E ; Canadian Cancer Trials Group, Queen's University, Kingston, Canada
Plante, Marie ; Centre Hospitalier Universitaire de Québec, Québec, Canada
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.
Publication date :
November 2024
Journal title :
Journal of Gynecologic Oncology
ISSN :
2005-0380
eISSN :
2005-0399
Publisher :
Korean Society of Gynecologic Oncology and Colposcopy, Korea south
Canadian Cancer Trials Group (CCTG) for operational support and the Canadian Institutes of Health Research (CIHR) for research funding.JSK discloses research funding from Michael Smith Health Research BC (formerly Michael Smith Foundation for Health Research),ownership of shares from Hexamer Therapeutics, and speaker fee from Astra Zeneca. MP discloses research funding from Astra Zeneca, royalties from UpToDate, and serving as an Advisory Board member for Serono-Merck.
National Library of Medicine. Radical versus simple hysterectomy and pelvic node dissection with low-risk early stage cervical cancer (SHAPE) [Internet]. Bethesda, MD: National Library of Medicine; 2024 [cited 2024 Mar 5]. Available from: https://clinicaltrials.gov/study/NCT01658930.
Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecol Oncol 2002;84:145-9. PUBMED | CROSSREF
Frumovitz M, Sun CC, Schmeler KM, Deavers MT, Dos Reis R, Levenback CF, et al. Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol 2009;114:93-9. PUBMED | CROSSREF
Stegeman M, Louwen M, van der Velden J, ten Kate FJ, den Bakker MA, Burger CW, et al. The incidence of parametrial tumor involvement in select patients with early cervix cancer is too low to justify parametrectomy. Gynecol Oncol 2007;105:475-80. PUBMED | CROSSREF
Wright JD, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, et al. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer 2007;110:1281-6. PUBMED | CROSSREF
Steed H, Capstick V, Schepansky A, Honore L, Hiltz M, Faught W. Early cervical cancer and parametrial involvement: is it significant? Gynecol Oncol 2006;103:53-7. PUBMED | CROSSREF
Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428-36. PUBMED | CROSSREF
Kadar N, Saliba N, Nelson JH. The frequency, causes and prevention of severe urinary dysfunction afteradical hysterectomy. Br J Obstet Gynaecol 1983;90:858-63. PUBMED | CROSSREF
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40. PUBMED | CROSSREF
Low JA, Mauger GM, Carmichael JA. The effect of Wertheim hysterectomy upon bladder and urethrfunction. Am J Obstet Gynecol 1981;139:826-34. PUBMED | CROSSREF
Sood AK, Nygaard I, Shahin MS, Sorosky JI, Lutgendorf SK, Rao SS. Anorectal dysfunction after surgictreatment for cervical cancer. J Am Coll Surg 2002;195:513-9. PUBMED | CROSSREF
Lee J, Byun HK, Im SH, Son WJ, Roh YH, Kim YB. Risk factors for lower extremity lymphedema aftesurgery in cervical and endometrial cancer. J Gynecol Oncol 2023;34:e28. PUBMED | CROSSREF
Drouin E, Classe JM, Hautecoeur P. 125 years of the Wertheim operation. What next? J Med Life 2023;16:341-3. PUBMED | CROSSREF
Zullo MA, Manci N, Angioli R, Muzii L, Panici PB. Vesical dysfunctions after radical hysterectomy focervical cancer: a critical review. Crit Rev Oncol Hematol 2003;48:287-93. PUBMED | CROSSREF
Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med 2024;390:819-29. PUBMED | CROSSREF
Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, et al. Sexual health and quality of life in patients with low-risk early-stage cervical cancer: results from GCIG/CCTG CX.5/SHAPE trial comparing simple versus radical hysterectomy. J Clin Oncol. Forthcoming 2024. PUBMED | CROSSREF
EuroQol. EQ-5D-3L [Internet]. Rotterdam: EuroQol; 2024 [cited 2023 Oct 26]. Available from: https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-3l.
Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One 2012;7:e31115. PUBMED | CROSSREF
Canadian Institute for Health Information. Patient cost estimator [Internet]. Ottawa: Canadian Institute for Health Information; 2023 [cited 2023 Oct 26]. Available from: https://www.cihi.ca/en/patient-cost-estimator.
Ministry of Health British Columbia. Medical services commission (MSC) payment schedule [Internet]. Victoria: Ministry of Health British Columbia; 2024 [cited 2023 Nov 6]. Available from: https://www2.gov. bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/msc_payment_schedule_oct_31_2023.pdf.
BC Cancer Provincial Pharmacy. Wholesale prices for pharmaceuticals. Vancouver, BC: BC Cancer Provincial Pharmacy; 2023.
Provincial Health Services Agency. Charges for radiotherapy services. Vancouver: BC Cancer; 2023.
Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, et al. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ Open 2020;8:E191-8. PUBMED | CROSSREF
CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
Statistics Canada. Employee wages by job permanency and union coverage, monthly, unadjusted for seasonality [Internet]. Ottawa: Statistics Canada; 2024 [cited 2024 Apr 17]. Available from: https://www150. statcan.gc.ca/t1/tbl1/en/tv.action?pid=1410006501.
Halliday D, Lau S, Vaknin Z, Deland C, Levental M, McNamara E, et al. Robotic radical hysterectomy: comparison of outcomes and cost. J Robot Surg 2010;4:211-6. PUBMED | CROSSREF
Statistics Canada. Employee wages by job permanency and union coverage, annual. Ottawa: Statistics Canada; 2023.
Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardio2008;52:2119-26. PUBMED | CROSSREF
Institute for Clinical and Economic Review. ICER 2019 perspectives on cost-effectiveness thresholranges. Boston, MA: Institute for Clinical and Economic Review; 2019.
York Health Economics Consortium. Net monetary benefit [Internet]. York: York Health Economics Consortium; 2016 [cited 2024 Apr 17]. Available from: https://yhec.co.uk/glossary/net-monetary-benefi
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force--6. Value Health 2012;15:835-42. PUBMED | CROSSREF
Canadian Cancer Society. Canadian cancer statistics 2023. Toronto: Canadian Cancer Society; 2023.
U.S. Cancer Statistics Working Group. Stage distribution (%) of new cancer cases, all ages, all races and ethnicities, cervix, United States, 2016–2020 [Internet]. [place unknown]: U.S. Cancer Statistics Working Group; 2024 [cited 2024 Apr 3]. Available from: https://gis.cdc.gov/Cancer/USCS/#/StageatDiagnosis/.
Centers for Disease Control and Prevention. Cervical cancer statistics [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2023 [cited 2024 Apr 29]. Available from: https://www.cdc.gov/cancer/cervical/statistics/index.htm.
35.
World Health Organization. Cervical cancer [Internet]. Geneva: World Health Organization; 2024 [cited 2024 Apr 3]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. Geneva: World Health Organization; 2020 [cited 2024 Apr 3]. Available from: https://www.who.int/publications/i/item/9789240014107.
Jewell EL, Smrtka M, Broadwater G, Valea F, Davis DM, Nolte KC, et al. Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health 2011;14:582-6. PUBMED | CROSSREF
Carneiro VCG, Batista TP, Andrade MR, Barros AV, Câmara LHLD, Ramalho NM, et al. Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER). Int J Gynecol Cancer 2023;33:498-503. PUBMED | CROSSREF
Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer 2021;31:1317-25. PUBMED | CROSSREF
Naumann RW. The SHAPE trial: is good is good enough? J Gynecol Oncol 2024;35:e107. PUBMED | CROSSREF